Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources

Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources

Ana Rodríguez-Regal,1 Laura Ramos-Rúa,2 Luis Anibarro-García,3 Ana María Lopez Real,4 María del Campo Amigo-Jorrín1 1Department of Neurology, Complejo Hospitalario Universitario de Pontevedra (CHUP), Pontevedra, Spain; 2Department of...

Full description

Bibliographic Details
Main Authors:	Rodríguez-Regal A, Ramos-Rúa L, Anibarro-García L, Lopez Real AM, Amigo-Jorrín MC
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-01-01
Series:	Patient Preference and Adherence
Subjects:	multiple sclerosis. dimethyl fumarate. annualized relapse rate. adverse effects. clinical practice
Online Access:	https://www.dovepress.com/effectiveness-of-dimethyl-fumarate-in-real-world-clinical-practice-and-peer-reviewed-article-PPA

Similar Items

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
by: Silvia Delgado, et al.
Published: (2021-02-01)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
by: Raed Alroughani, et al.
Published: (2021-01-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Angel Chinea, et al.
Published: (2020-05-01)

A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Mitzi J. Williams, et al.
Published: (2020-05-01)

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)

Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases
by: Azzam Maghazachi, et al.
Published: (2016-07-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
by: Dipen Sangurdekar, et al.
Published: (2019-11-01)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
by: Albrecht Philipp, et al.
Published: (2012-07-01)

[Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-03-01)

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
by: Martina Burlando, et al.
Published: (2021-10-01)

Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
by: Narapureddy B, et al.
Published: (2019-10-01)

The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility
by: Lorena Lorefice, et al.
Published: (2021-09-01)

SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting
by: Chiara Zecca, et al.
Published: (2020-12-01)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
by: Michelle Allan, et al.
Published: (2019-12-01)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
by: Ozel O, et al.
Published: (2019-12-01)

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
by: Robert Zivadinov, et al.
Published: (2019-03-01)

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
by: Stephanie Kourakis, et al.
Published: (2020-10-01)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
by: Giovanna Malara, et al.
Published: (2021-05-01)

Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
by: Keita Takahashi, et al.
Published: (2021-02-01)

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
by: Cara A. Timpani, et al.
Published: (2021-12-01)

Proposed Neuroimmune Roles of Dimethyl Fumarate, Bupropion, <i>S</i>-Adenosylmethionine, and Vitamin D<sub>3</sub> in Affording a Chronically Ill Patient Sustained Relief from Inflammation and Major Depression
by: Navzer D. Sachinvala, et al.
Published: (2020-08-01)

Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study
by: Damiano Marastoni, et al.
Published: (2019-07-01)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
by: Vanesa Cunill, et al.
Published: (2018-05-01)

Dimethyl fumarate inhibits antibody-induced platelet destruction in immune thrombocytopenia mouse
by: Huan Tong, et al.
Published: (2021-08-01)

Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge
by: Hallel C. Paraiso, et al.
Published: (2018-03-01)

Exploring the Use of Dimethyl Fumarate as Microglia Modulator for Neurodegenerative Diseases Treatment
by: Maria Rosito, et al.
Published: (2020-08-01)

Dimethyl fumarate: the new tableted preparation for the treatment of multiple sclerosis
by: E. V. Popova, et al.
Published: (2015-12-01)

Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma
by: Kaiyuan Chen, et al.
Published: (2021-02-01)

Dimethyl fumarate ameliorates endotoxin-induced acute kidney injury against macrophage oxidative stress
by: Kejun Zhou, et al.
Published: (2021-01-01)

Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells
by: Onofrio Laselva, et al.
Published: (2021-08-01)

Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis
by: Smriti Ojha, et al.
Published: (2018-06-01)

Glatiramer Acetate, Dimethyl Fumarate and Monomethyl Fumarate Up-Regulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance their Chemotaxis and Cytotoxicity. Implications for Cancer Immunotherapy
by: Azzam Maghazachi, et al.
Published: (2016-10-01)

Neuroprotection and immunomodulation by dimethyl fumarate and a heterologous fibrin biopolymer after ventral root avulsion and reimplantation
by: Paula R. G. Kempe, et al.

Antioxidant and Anti-Inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases
by: Sarah A. Scuderi, et al.
Published: (2020-07-01)

Dimethyl fumarate abrogates dust mite‐induced allergic asthma by altering dendritic cell function
by: Anil K. Jaiswal, et al.
Published: (2019-09-01)

Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate
by: Shiri Li, et al.
Published: (2021-01-01)